Gilead Sciences, Inc. (NASDAQ:GILD)‘s stock had its “buy” rating restated by investment analysts at Cowen and Company in a research report issued on Friday. They currently have a $100.00 target price on the biopharmaceutical company’s stock. Cowen and Company’s price target suggests a potential upside of 31.86% from the stock’s current price.
The analysts wrote, “Effective Jan. 1, the U.S. price of Atripla has been increased by 2.3%.””
A number of other analysts also recently weighed in on GILD. Berenberg Bank initiated coverage on Gilead Sciences in a research report on Monday, September 12th. They set a “buy” rating and a $112.00 target price for the company. Jefferies Group restated a “buy” rating and set a $91.00 price objective on shares of Gilead Sciences in a research report on Monday, September 12th. Credit Suisse Group dropped their price objective on Gilead Sciences from $115.00 to $95.00 and set an “outperform” rating for the company in a research report on Wednesday, September 14th. Zacks Investment Research upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Wednesday, September 14th. Finally, Piper Jaffray Companies set a $108.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a research report on Thursday, September 22nd. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, nineteen have given a buy rating and two have given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $96.18.
Shares of Gilead Sciences (NASDAQ:GILD) opened at 75.84 on Friday. Gilead Sciences has a 12 month low of $70.83 and a 12 month high of $103.10. The company has a 50-day moving average price of $73.96 and a 200-day moving average price of $77.97. The firm has a market capitalization of $99.92 billion, a price-to-earnings ratio of 7.01 and a beta of 1.20.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, November 1st. The biopharmaceutical company reported $2.75 earnings per share for the quarter, missing analysts’ consensus estimates of $2.87 by $0.12. The company had revenue of $7.40 billion for the quarter, compared to the consensus estimate of $7.47 billion. Gilead Sciences had a net margin of 47.74% and a return on equity of 100.57%. The business’s revenue was down 9.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.22 earnings per share. Equities analysts forecast that Gilead Sciences will post $11.42 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Thursday, December 29th. Investors of record on Thursday, December 15th were issued a dividend of $0.47 per share. The ex-dividend date was Tuesday, December 13th. This represents a $1.88 dividend on an annualized basis and a yield of 2.48%. Gilead Sciences’s dividend payout ratio (DPR) is currently 17.44%.
In other Gilead Sciences news, insider John C. Martin sold 73,337 shares of the firm’s stock in a transaction on Tuesday, January 3rd. The stock was sold at an average price of $73.59, for a total value of $5,396,869.83. Following the completion of the sale, the insider now directly owns 3,204,433 shares of the company’s stock, valued at $235,814,224.47. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director John W. Madigan sold 105,000 shares of the firm’s stock in a transaction on Friday, November 18th. The stock was sold at an average price of $74.86, for a total value of $7,860,300.00. Following the completion of the sale, the director now directly owns 121,761 shares of the company’s stock, valued at $9,115,028.46. The disclosure for this sale can be found here. Corporate insiders own 1.40% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the company. Capital Research Global Investors increased its stake in Gilead Sciences by 9.7% in the third quarter. Capital Research Global Investors now owns 27,886,530 shares of the biopharmaceutical company’s stock worth $2,206,382,000 after buying an additional 2,474,271 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Gilead Sciences by 0.6% in the third quarter. Bank of New York Mellon Corp now owns 26,786,930 shares of the biopharmaceutical company’s stock worth $2,119,382,000 after buying an additional 169,701 shares in the last quarter. BlackRock Fund Advisors increased its stake in Gilead Sciences by 6.8% in the third quarter. BlackRock Fund Advisors now owns 26,032,555 shares of the biopharmaceutical company’s stock worth $2,059,696,000 after buying an additional 1,663,268 shares in the last quarter. Capital World Investors increased its stake in Gilead Sciences by 28.3% in the second quarter. Capital World Investors now owns 15,318,948 shares of the biopharmaceutical company’s stock worth $1,277,907,000 after buying an additional 3,380,000 shares in the last quarter. Finally, Alliancebernstein L.P. increased its stake in Gilead Sciences by 17.0% in the second quarter. Alliancebernstein L.P. now owns 13,346,714 shares of the biopharmaceutical company’s stock worth $1,113,383,000 after buying an additional 1,942,138 shares in the last quarter. 73.43% of the stock is owned by institutional investors and hedge funds.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
What are top analysts saying about Gilead Sciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Gilead Sciences Inc. and related companies.